U-90042
In today's article we are going to delve into the topic of U-90042, exploring its different facets and its relevance in today's society. U-90042 is a topic that has captured the attention of people of all ages and backgrounds, and its importance has been increasing in recent years. Through this article, we hope to offer a broad and detailed overview of U-90042, giving our readers the opportunity to gain deeper knowledge about this topic and its impact on our lives. From its origin to its implications in various areas, we will immerse ourselves in an exhaustive analysis that allows our readers to better understand U-90042 and its implications in today's society.
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H13ClN6O |
| Molar mass | 352.78 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
U-90042 is a sedative and hypnotic drug used in scientific research. It has similar effects to sedative-hypnotic benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic.
U-90042 is a GABAA agonist acting primarily at the α1, α3 and α6 subtypes, with a Ki of 7.8nM at α1, 9.5nM at α3 and 11.0nM at α6. It produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys, but does not produce amnesia and blocks the amnestic effect of diazepam, reflecting its different subtype affinity compared to benzodiazepine drugs. It was developed by a team at Novo Nordisk in the 1980s.
References
- ^ Tang AH, Smith MW, Carter DB, Im WB, VonVoigtlander PF (November 1995). "U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes". The Journal of Pharmacology and Experimental Therapeutics. 275 (2): 761–7. PMID 7473164.
- ^ US 5100895, "Heterocyclic compounds and their preparation and use"
 | This sedative-related article is a stub. You can help Wikipedia by expanding it. |